Morgan Stanley
TNGX icon

Morgan Stanley’s Tango Therapeutics TNGX Stock Holding History

Morgan Stanley’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Sell
510,778
-966,710
-65% -$23.9M ﹤0.01% 3297
2026
Q1 		$30.9M Buy
1,477,488
+55,694
+4% +$775K ﹤0.01% 2553
2025
Q4 		$12.6M Buy
1,421,794
+1,170,001
+465% +$10.1M ﹤0.01% 3395
2025
Q3 		$2.12M Sell
251,793
-282,828
-53% -$1.91M ﹤0.01% 4741
2025
Q2 		$2.74M Buy
534,621
+284,102
+113% +$702K ﹤0.01% 4508
2025
Q1 		$343K Sell
250,519
-69,551
-22% -$171K ﹤0.01% 5505
2024
Q4 		$989K Sell
320,070
-21,907
-6% -$102K ﹤0.01% 5095
2024
Q3 		$2.63M Buy
341,977
+98,608
+41% +$941K ﹤0.01% 4458
2024
Q2 		$2.09M Buy
243,369
+63,850
+36% +$493K ﹤0.01% 4535
2024
Q1 		$1.43M Buy
179,519
+36,112
+25% +$387K ﹤0.01% 4769
2023
Q4 		$1.42M Sell
143,407
-49,917
-26% -$433K ﹤0.01% 4742
2023
Q3 		$2.18M Buy
193,324
+139,130
+257% +$848K ﹤0.01% 4344
2023
Q2 		$180K Sell
54,194
-21,397
-28% -$77K ﹤0.01% 5691
2023
Q1 		$299K Buy
75,591
+46,672
+161% +$271K ﹤0.01% 5517
2022
Q4 		$210K Buy
28,919
+5,753
+25% +$40.5K ﹤0.01% 5652
2022
Q3 		$83K Buy
23,166
+4,734
+26% +$20.2K ﹤0.01% 6175
2022
Q2 		$84K Buy
18,432
+2,717
+17% +$16.5K ﹤0.01% 6365
2022
Q1 		$119K Buy
15,715
+6,878
+78% +$59.6K ﹤0.01% 6218
2021
Q4 		$96K Buy
8,837
+6,990
+378% +$84.1K ﹤0.01% 6468
2021
Q3 		$24K Buy
+1,847
New +$22.1K ﹤0.01% 7039

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Morgan Stanley's TNGX Position: Q2 2026 in Review

Morgan Stanley reduced its Tango Therapeutics (TNGX) stake by 65% in Q2 2026, selling an estimated $23.9M and leaving 510,778 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

Morgan Stanley first reported a position in TNGX in Q3 2021 and has held it in 20 quarters since. The position peaked at $30.9M in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Morgan Stanley held 510,778 shares of Tango Therapeutics worth $16M as of Q2 2026.
  • Morgan Stanley sold 966,710 Tango Therapeutics shares in Q2 2026, an estimated $23.9M.
  • Tango Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3297 holding.
  • Morgan Stanley first reported a position in Tango Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Tango Therapeutics position peaked at $30.9M in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.